| 21/26 | US=6 / Quimioterapia Airley R. Checkpoint protein kinases as novel targets - mammalian target of rapamycin (mTOR). In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 245-8. ISBN 978-0-470-09254-5. CHECKPOINT; PROTEINAS QUINASES; MTOR; ALVO DA RAPAMICINA EM MAMIFEROS; ATIVACAO DE MTOR; ANTICANCERIGENOS ALVO MTOR |
| 22/26 | US=6 / Quimioterapia Airley R. Telomerase. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 249-54. ISBN 978-0-470-09254-5. |
| 23/26 | US=6 / Quimioterapia Airley R. Histone deacetylase: an epigenetic drug target. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 255-63. ISBN 978-0-470-09254-5. INIBIDORES DE HDAC; HISTONA DEACETILASE; DROGA EPIGENETICA; HDAC; EMBALAGEM DE DNA |
| 24/26 | US=6 / Quimioterapia Airley R. Pharmaceutical problems in cancer chemotherapy. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 265-80. ISBN 978-0-470-09254-5. PROBLEMAS FARMACEUTICOS EM QUIMIOTERAPIA; MANIFESTACAO DE TOXICIDADE; REGIME DE TOXICIDADE; RESISTENCIA A DROGAS; COMPLICACOES FARMACEUTICAS |
| 25/26 | US=6 / Quimioterapia Airley R. Oncology pharmacy at home and abroad. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 281-2. ISBN 978-0-470-09254-5. |
| 26/26 | US=6 / Quimioterapia Airley R. Practice exam questions. In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 283-98. ISBN 978-0-470-09254-5. |